24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: Follow up using brain spectroscopy

Damien Galanaud a, Ayman Tourbah b, Stéphane Lehéricy a, Nathalie Leveque c, Bénédicte Heron d, Thierry Billette de Villemeur d, Nathalie Guffon c, François Feillet f, Nicole Baumann g, Marie T. Vanier h, Frédéric Sedel c,*

a Department of Neuroradiology and Center for Neuroimaging Research—CENIR, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, France
b Department of Neurology, Centre Hospitalier Universitaire de Reims, France and INSERM US46, UPMC, Paris
c Federation of Nervous System Diseases and Reference Center for lysosomal diseases, Assistance Publique Hôpitaux de Paris, Salpêtrière Hospital, 47 Boulevard de l’Hôpital, 75651 Paris cedex 13, France
d Department of Neuropediatrics, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, France
e Department of Pediatrics, Medical unit, INSERM U 724 Centre Hospitalier Universitaire de Nancy, France
f Unité mixte de recherche INSERM U-711; UPMC, Hôpital de la Salpêtrière, Paris, France
g Institut National de la Santé et de la Recherche Médicale, Unit 820, Lyon Laennec Medical School, France

A R T I C L E   I N F O

Article history:
Received 29 August 2008
and in revised form 2 October 2008
Accepted 2 October 2008
Available online xxx

Keywords:
Niemann-Pick C
Miglustat
Zavesca
Magnetic resonance spectroscopy
Inherited metabolic diseases
Inborn errors of metabolism
Substrate reduction therapy

A B S T R A C T

Niemann-Pick C (NPC) is a fatal progressive neurolipidosis. Miglustat, an inhibitor of glycosphingolipid synthesis, has been proposed to treat patients but questions remain regarding its efficacy. A major problem has been the lack of suitable objective efficacy endpoints. Three adults with NPC were treated with miglustat for 24 months. Efficacy of treatment was assessed clinically and using brain magnetic resonance spectroscopy. All patients reported mild clinical improvement or stabilization. Furthermore, a sustained decrease in the choline/creatinine ratio was observed in all three patients over time. Although these preliminary results require confirmation on a larger cohort of patients, they suggest that miglustat has some beneficial effect on brain dysfunction in NPC and that MRS could be used routinely as a non invasive surrogate marker of treatment efficacy.

© 2008 Elsevier Inc. All rights reserved.

Introduction

Niemann-Pick disease type C (NPC) is a progressive neurological lysosomal storage disease of autosomal recessive inheritance. NPC arises from mutations in two genes, NPC1 (95% of patients) and NPC2, that play a role in intracellular cholesterol and glycolipid trafficking [1]. While large amounts of free cholesterol accumulate in peripheral organs, the most conspicuous storage in brain concerns glycosphingolipids, essentially GM2 and GM3 gangliosides. Mechanisms by which gangliosides accumulate are probably multiple and the relationship between glycolipid storage and abnormalities in cholesterol transport are still controversial. Neurological signs of NPC arise both from neuronal loss and neuronal dysfunction [2]. While symptoms related to cell loss are less likely to be improved by treatments, restoring cellular homeostasis by any therapeutic approach could potentially reverse cellular dysfunction and then provide clinical stabilization or improvement.

Adult forms of NPC are characterized by psychiatric disorders, vertical supranuclear gaze palsy, cerebellar ataxia, cognitive deficits, movement disorders, gelastic cataplexy and hepatosplenomegaly [3]. Death usually occurs on average 12 years after the onset of psychiatric or neurological signs. N-butyldesoxynojirimycin (NB-DNJ, OGT 918, miglustat) is an inhibitor of glucosylceramide synthetase, currently approved for the treatment of Gaucher type I disease [4]. It also inhibits the biosynthesis of all glycolipids derived from the glucosylceramide precursor, among which most gangliosides. Consequently, this compound has been tested in animal models of NPC: treatment with miglustat delayed onset of neurological symptoms, prolonged survival and improved brain neuropathology [5]. However, in humans, results are equivocal. Several case reports described some stabilization or improvement in adult patients but not in children [6–8]: as in Gaucher disease type II, early onset forms of NPC are usually more severe, rapidly...
progress and are therefore less accessible to treatments. A recent open-randomized controlled trial in patients with a late onset disease, reported stabilization or improvement of horizontal saccade velocity, swallowing and ambulatory index, however, statistical difference was weak [9].

A major problem in previous trials with miglustat in NPC has been the lack of quantifiable objective markers that could be predictive of clinical efficacy. Neurological examination can be quantified through clinical scales but these are not fully appropriate to NPC: given the slow mechanism of action of miglustat, as observed in Gaucher disease [10] and given the probable irreversible neurological damage, a rapid clinical improvement is not expected.

Here we report the follow up with MRS of three patients treated with miglustat for 24 months. Interestingly, we observed a decrease of the choline/creatinine ratio in all three patients.

Methods

From March 2006 to December 2008, nine patients with NPC were treated with miglustat off license in France. Patients who accessed to treatment had relative late-onset-diseases (juvenile or adult forms) and were relatively autonomous i.e., without gastric tube, dementia or severe psychiatric problems. Follow up with serial brain MRS was obtained in three patients followed at the Pitié-Salpêtrière Hospital (Paris). Only these three patients are reported here. All patients were treated initially with a dose of 600 mg/day that was decreased to 300 mg after 3–6 months in patient 2.

The main clinical characteristics, genotypes, and clinical evolution under treatment with miglustat are summarized in Table 1. In brief, after 24 months of treatment, all three patients exhibited mild improvement or stabilization regarding swallowing, dysarthria, awareness or ambulation. Improvement was the most obvious in patient 1: after 18 months, this patient did not present any paranoid delusion (acute episodes of delusion occurred around twice a year before treatment, and she had mild paranoid delusion in between these attacks), she did not fall anymore (falls were frequent before treatment) and she did not present any dysphagia whereas dysphagia occurred once daily before treatment. Patient 2 remained essentially stable after 12 months (last follow up) with some improvement of dysphagia: dysphagia worsened during the same period of time (Table 1).

MRI and MR spectroscopy (MRS)

MRS and MRI were obtained at baseline and after 12 (M12), 18 (M18) and 24 (M24) months in all patients except in patient 2 for whom the MRS at M18 could not be performed.

Table 1

<table>
<thead>
<tr>
<th>Cases</th>
<th>Gender</th>
<th>Current age (years)</th>
<th>Age at neurological onset (y)</th>
<th>Genotype</th>
<th>Major Clinical signs at treatment onset</th>
<th>Dosage of miglustat</th>
<th>clinical evolution at last follow up</th>
<th>Adverse effects</th>
<th>Disability scale at baseline (total)</th>
<th>Disability scale at month 24 (total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>23</td>
<td>19</td>
<td>p.V950M/p.I1061T</td>
<td>Psy, Cog, At, Dys, VSO, Sm</td>
<td>200 mg tid M0 to M6 100 mg tid M6 to M24</td>
<td>Improvement of walking, swallowing, dysarthria and awareness</td>
<td>Weight loss, diarrhea</td>
<td>A3 M2 L2 S3 (10/18)</td>
<td>A2 M2 L2 S2 (8/18)</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>21</td>
<td>17</td>
<td>p.I1061T/p.G538R</td>
<td>Cog, Dys, VSO, Hea, Sm</td>
<td>200 mg tid M0 to M24</td>
<td>Slight improvement of swallowing and dysarthria</td>
<td>None</td>
<td>A2 M2 L2 S3 (9/18)</td>
<td>A2 M2 L2 S2 (8/18)</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>38</td>
<td>16</td>
<td>p.G992R/p.N452fs</td>
<td>Cog, Md, At, VSO, Sm</td>
<td>200 mg tid M0 to M3 100 mg tid M3 to M24</td>
<td>Improvement of dysarthria and awareness, worsening of gait</td>
<td>Worsening of myoclonus reversible after decreased dosage</td>
<td>A4 M4 L2 S2 (12/18)</td>
<td>A5 M4 L2 S2 (13/18)</td>
</tr>
</tbody>
</table>

Abbreviations: At, ataxia; Cog, cognitive disorder (excluding psychiatric symptoms); Dys, dystonia; F, female; Hea, hearing loss; M, male; Psy, psychiatric signs; Sm, splenomegaly; VSO, vertical supranuclear ophthalmoplegia.

* See the methods section.

Table 2
Measurements of main metabolic peak ratios in the centrum semiovale in three patients treated with miglustat for 24 months.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Cho/Cr Baseline</th>
<th>M12</th>
<th>M18</th>
<th>M24</th>
<th>NAA/Cr Baseline</th>
<th>M12</th>
<th>M18</th>
<th>M24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>1.24, 1.269</td>
<td>0.93, 0.76</td>
<td>2.06</td>
<td>2.30</td>
<td>2.13, 2.14</td>
<td>1.27, 1.07</td>
<td>2.30, 2.12</td>
<td>2.57</td>
</tr>
<tr>
<td>Patient 2</td>
<td>1.41, 1.246</td>
<td>NA</td>
<td>1.05, 2</td>
<td>1.97, NA</td>
<td>1.98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient 3</td>
<td>1.27, 1.27</td>
<td>1.07, 1.12</td>
<td>2.26, 2.27</td>
<td>2.57</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean values</td>
<td>1.3, 1.26</td>
<td>1.01</td>
<td>0.98</td>
<td>2.12</td>
<td>2.18, 2.13</td>
<td>2.23</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

M12, M18, M24 values after 12, 18 and 24 months of treatment with miglustat, NA, non available. Cho/Cr and NAA/Cr ratios were calculated automatically from the raw data using the Probe Q software. Position of the voxel of interest is shown in Fig. 1.

Discussion

We observed a sustained decrease in the Cho/Cr ratio in three NPC patients treated with miglustat for up to 24 months. This ratio decreased after 18 months of treatment and was observed whatever the dose of miglustat (600 mg vs 300 mg/day). Since Cho/Cr is considered as a marker of brain dysfunction, it is suggested that miglustat has a beneficial effect over time. Interestingly, the same effect was observed in patient 3 who had 22 years of symptomatic disease versus 4 years in patients 1 and 2 suggesting that even in advanced stages, some brain dysfunction may still be reversible.

This study has important methodological limitations. First, the small number of patients did not allow valid statistical analysis. It is assumed that all results reported here need to be confirmed in a larger cohort of patients.

Second, this is an uncontrolled study. We did not perform sequential brain MRI in untreated NPC patients so that we do not have a precise idea of the natural evolution of MRS in NPC. In the worst case, the change in Cho/Cr ratios observed in our patients could simply represent progressive changes in the white matter of patients as getting older and sicker over a 2-year period. Although we can not exclude formally this possibility, we do not favor it for two reasons: (1) Cho/Cr was about the same in patient 3 with a more advanced disease as compared to patients 1 and 2. (2) Disease progression is expected to cause a decrease in NAA (considered as a marker of neuronal viability) and an increase in choline (considered as a marker of membrane destruction or gliosis) [13,14]. However, NAA remained stable during 24 months whereas choline decreased during the same time suggesting a direct effect of miglustat.

Third, some variations in the position and size of the volume of interest could account for Cho/Cr decrease. This may be the case for the last examination of patient 1, and such a variation is diffi-
cult to avoid in disabled patients, even with careful repositioning in the magnet. However, it is unlikely that variation in the voxel size or position is responsible for the decrease in the Cho/Cr ratio observed at all time points in all patients.

Fourth, the choice of the cerebral white matter (centrum ovale or semi ovale) to follow disease’s progression seems paradoxical since NPC mainly affects basal ganglia, cerebellum or brain stem [1]. This choice was motivated by practical considerations: MRS spectra were of better quality in this region compared to cerebellum or basal ganglia.

Fifth, it is still not known, to what extent spectroscopic changes can be translated into clinical improvement. While the MRS changes are encouraging, their clinical and pathological significance is elusive. Indeed, the clinical outcomes in our patients as in previous studies were at best modest.

MRS has been used for many years in the diagnosis and follow up of nervous system diseases including inborn errors of metabolism [14]. Although abnormalities in metabolite peaks have limited diagnostic value, they may constitute useful quantitative surrogate markers to monitor treatment efficacy. For instance, in patients with adrenoleukodystrophy, the efficacy of bone marrow transplantation is correlated in individual cases with a decrease in Cho and an increase in NAA [15]. While MRS has been proposed to measure neuronal dysfunction in vivo in NPC it has not been used in therapeutic trials so far [13]. The procedure used in our study is however, very simple: it is based on a single voxel acquisition in the centre ovale or semioval at long echo time with a simple automatic ratio calculation by the machine.

Although results reported here need to be confirmed, they suggest that (1) MRS could be used routinely as a non invasive quantitative and objective surrogate marker of treatment efficacy and (2) treatment with miglustat should be efficacious in NPC after a relative long period of time and this effect would exist even in advanced stages of the disease. The need for comprehensive studies of the course of untreated NPC in a large multicenter series of patients with the different categories of clinical presentation is increasingly pressing if we are to gain further useful therapeutic insight into this disorder.

References